Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM inact mut||prostate cancer||sensitive||Olaparib||FDA approved - Has Companion Diagnostic||Actionable||In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) treatment improved progression-free survival (7.4 vs 3.6 mo, HR=0.34, p<0.001), objective response rate (33%, 28/84 vs 2%, 1/43, OR=20.86, p<0.001), and median time to pain progression (HR=0.44, p=0.02) compared to control in patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious mutations in BRCA1/2 or ATM who progressed on hormone therapy (PMID: 32343890; NCT02987543).||detail... 32343890 detail...|
|ATM inact mut||prostate cancer||sensitive||Olaparib||Phase II||Actionable||In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020).||26510020|
|ATM inact mut||prostate cancer||sensitive||Olaparib||Guideline||Actionable||Lynparza (olaparib) is included in guidelines as second-line therapy post androgen receptor-directed therapy for patients with metastatic castration-resistant prostate cancer harboring pathogenic mutations in ATM (NCCN.org).||detail...|
|ATM inact mut||prostate cancer||sensitive||Olaparib||Phase II||Actionable||In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 36.8% (7/19) and a RECIST objective response rate of 8.3% (1/12) in patients with castration-resistant prostate cancer harboring deleterious ATM mutations (PMID: 31806540; NCT01682772).||31806540|
|PubMed Id||Reference Title||Details|
|(26510020)||DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.||Full reference...|
|Lynparza (olaparib) FDA Drug Label||Full reference...|
|(31806540)||Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.||Full reference...|
|(32343890)||Olaparib for Metastatic Castration-Resistant Prostate Cancer.||Full reference...|